TRANSCAN-3 launches its third Joint Transnational Call for research proposals (JTC 2023) on the following topic:

“Translational research on cancer epigenetics”

The expected outcome of the call is to improve the efficacy of current detection, diagnosis, prognosis and treatment of cancers, through the development of novel approaches based on a better understanding of cancer epigenetics. The specific objectives of this funding opportunity are to stimulate new partnerships between researchers and clinicians and support original, high-quality projects, with significant clinical impact.

In the context of translational research, this topic will comprise two general aims, each with several aims, which concur to the possible clinical applications. Proposals should cover one or several of the specific aims and should be built from a sound hypothesis.

Aim 1: The role of epigenetics in cancer initiation and progression.

• Specific aim 1.1: To understand cancer initiation and progression by characterisation of the epigenetic landscape.
• Specific aim 1.2: To define epigenetic features of cells in the tumour microenvironment that may promote tumour progression (e.g., immune cells, vascular cells, microbiota).
• Specific aim 1.3: To study the role of epigenetic modifications as predictors of cell persistence or treatment resistance.
• Specific aim 1.4: To validate epigenetic markers useful to improve early detection and diagnosis by exploring the correlation between epigenetics and clinical cancer manifestation.

Aim 2: Validation of new epigenetics-based therapeutic strategies to limit cancer progression, prevent relapse/recurrence or increase the efficiency or reduce toxicity of existing anti-cancer therapies.

• Specific aim 2.1: To validate novel therapeutic targets (novel targets should be evaluated in translational studies with regard to their impact on treatment efficacy, safety and patient reported outcomes).
• Specific aim 2.2: To study the potential use of epigenetic modulators to overcome resistance to anti-cancer therapies.
• Specific aim 2.3: To develop novel epidrugs/therapeutic approaches, through phase I and II clinical trials (investigating combinations of available treatments, new therapeutics, new administration schemes, etc.) to improve safety and efficacy of treatments (objective responses; patient reported outcomes regarding morbidity and quality of life; …).
• Specific aim 2.4: To develop novel theranostic approaches involving epigenetics of cancer. Approaches combining diagnostic (imaging technics) and targeted treatment to detect cancer cells and assess treatment efficacy (radionuclide, radiopharmaceuticals, nanoparticles, nanomaterial, …).

Timeline and eligibility criteria:

• July 21^st, 2023 – pre-proposal submission
• December 15^th, 2023 – full-proposal submission
• Funding for joint projects with three to six partners from at least three different participating countries (see link below)

Further information:

https://transcan.eu/funding/calls/joint-call-jtc-2023-.kl

Contact at EPC:

© TU Dresden

Project Manager

Name

Mr Dr. Stefan Schuldt

ERA-Nets, BMBF Complementary measures

Send email

Send encrypted email via the SecureMail portal (for TUD external users only).

Contact Information

Organization Name

European Project Center

European Project Center

Address work

Visiting address:

FAL Falkenbrunnen BT-A Würzburger Straße 35

01187 Dresden

Show map of this location.

work Tel.